Inhibikase Therapeutics annual operating margin
2020
2021
2022
2023
Inhibikase Therapeutics's operating margin was −7,711.98% for fiscal 2023.
View full Inhibikase Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −7,711.98% | +6974.19 pp |
| 2022 | 2022-12-31 | −14,686.17% | −14209.94 pp |
| 2021 | 2021-12-31 | −476.23% | −72.71 pp |
| 2020 | 2020-12-31 | −403.52% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q4 2023 | 2023-12-31 | −440,356,600.00% | −440349780.36 pp |
| Q3 2023 | 2023-09-30 | −5,993.38% | +55906.20 pp |
| Q2 2023 | 2023-06-30 | −5,328.07% | +65489.07 pp |
| Q1 2023 | 2023-03-31 | −7,307.62% | +2773.84 pp |
| Q4 2022 | 2022-12-31 | −6,819.64% | +252514.77 pp |
| Q3 2022 | 2022-09-30 | −61,899.59% | −60538.37 pp |
| Q2 2022 | 2022-06-30 | −70,817.14% | −70624.31 pp |
| Q1 2022 | 2022-03-31 | −10,081.46% | −9894.89 pp |
| Q4 2021 | 2021-12-31 | −259,334.41% | −258629.76 pp |
| Q3 2021 | 2021-09-30 | −1,361.22% | +400.22 pp |
| Q2 2021 | 2021-06-30 | −192.83% | −4.33 pp |
| Q1 2021 | 2021-03-31 | −186.56% | +12.86 pp |
| Q4 2020 | 2020-12-31 | −704.66% | — |
| Q3 2020 | 2020-09-30 | −1,761.44% | — |
| Q2 2020 | 2020-06-30 | −188.50% | — |
| Q1 2020 | 2020-03-31 | −199.42% | — |
Across the available reported history, Inhibikase Therapeutics's operating margin increased from −14,686.17% to −7,711.98%, a change of +6974.19 percentage points. The latest reported quarter, Q4 2023, shows −440,356,600.00%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Inhibikase Therapeutics filings at SEC.gov ↗